Skip to main content

Advertisement

SpringerLink
Log in

Association between serum amyloid A and obesity: a meta-analysis and systematic review

  • Review
  • Published:
Inflammation Research Aims and scope Submit manuscript

Abstract

Background

Emerging evidence indicates an association of the acute-phase protein serum amyloid A (SAA) with obesity. Here we review and summarize quantitatively the available data related to this association.

Methods

PubMed was systematically searched using the terms “serum amyloid A” and “obesity.” Eighty-one relevant studies between January 1966 and July 2009 were identified. Of these, only 11 cross-sectional studies and 10 prospective studies with successful interventions met our inclusion criteria for the meta-analysis. All analyses were conducted using the Comprehensive Meta-Analysis software. Literature pertaining to the relationship between SAA and other inflammatory markers, and the association between SAA and obesity-related disorders, such as cardiovascular diseases, atherosclerosis, diabetes, and insulin resistance was also reviewed.

Results

A strong association between body mass index and SAA levels was found in the 11 cross-sectional studies. The overall correlation coefficient is 0.230 (95% CI 0.160–0.297, P < 0.0005). The ten prospective studies were subsequently analyzed, and the difference in SAA levels before and after weight loss, expressed as standardized mean difference was −0.480 (95% CI −0.678 to −0.283, P < 0.0005). We discuss some potential underlying mechanisms and clinical applications for reducing SAA levels in obesity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–7.

    Article  PubMed  CAS  Google Scholar 

  2. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115:1111–9.

    PubMed  CAS  Google Scholar 

  3. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor-necrosis-factor-alpha—direct role in obesity-linked insulin resistance. Science. 1993;259:87–91.

    Article  PubMed  CAS  Google Scholar 

  4. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131–5.

    Article  PubMed  CAS  Google Scholar 

  5. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med. 2002;8:75–9.

    Article  PubMed  CAS  Google Scholar 

  6. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796–808.

    PubMed  CAS  Google Scholar 

  7. Xu HY, Barnes GT, Yang Q, Tan Q, Yang DS, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821–30.

    PubMed  CAS  Google Scholar 

  8. Malle E, de Beer FC. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest. 1996;26:427–35.

    Article  PubMed  CAS  Google Scholar 

  9. Gabay C, Kushner I. Mechanisms of disease: acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–54.

    Article  PubMed  CAS  Google Scholar 

  10. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology—a proposal for reporting. JAMA. 2000;283:2008–12.

    Article  PubMed  CAS  Google Scholar 

  11. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.

    Article  PubMed  Google Scholar 

  12. Kraja AT, Province MA, Arnett D, Wagenknecht L, Tang W, Hopkins PN, et al. Do inflammation and procoagulation biomarkers contribute to the metabolic syndrome cluster? Nutr Metab (Lond). 2007;4:28.

    Article  CAS  Google Scholar 

  13. Liu J, Young TK, Zinman B, Harris SB, Connelly PW, Hanley AJG. Lifestyle variables, non-traditional cardiovascular risk factors, and the metabolic syndrome in an aboriginal Canadian population. Obesity (Silver Spring). 2006;14:500–8.

    Article  Google Scholar 

  14. Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C. The implication of obesity and central fat on markers of chronic inflammation: the ATTICA study. Atherosclerosis. 2005;183:308–15.

    Article  PubMed  CAS  Google Scholar 

  15. Thorand B, Baumert J, Doring A, Herder C, Kolb H, Rathmann W, et al. Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis. 2006;184:216–24.

    Article  PubMed  CAS  Google Scholar 

  16. Tannock LR, O’Brien KD, Knopp RH, Retzlaff B, Fish B, Wener MH, et al. Cholesterol feeding increases C-reactive protein and serum amyloid A levels in lean insulin-sensitive subjects. Circulation. 2005;111:3058–62.

    Article  PubMed  CAS  Google Scholar 

  17. Poitou C, Viguerie N, Cancello R, De Matteis R, Cinti S, Stich V, et al. Serum amyloid A: production by human white adipocyte and regulation by obesity and nutrition. Diabetologia. 2005;48:519–28.

    Article  PubMed  CAS  Google Scholar 

  18. Verdaet D, Dendale P, De Bacquer D, Delanghe J, Block P, De Backer G. Association between leisure time physical activity and markers of chronic inflammation related to coronary heart disease. Atherosclerosis. 2004;176:303–10.

    Article  PubMed  CAS  Google Scholar 

  19. Connelly PW, Hanley AJ, Harris SB, Hegele RA, Zinman B. Relation of waist circumference and glycemic status to C-reactive protein in the Sandy Lake Oji-Cree. Int J Obes Relat Metab Disord. 2003;27:347–54.

    Article  PubMed  CAS  Google Scholar 

  20. van Dielen FM, van’t Veer C, Schols AM, Soeters PB, Buurman WA, Greve JW. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord. 2001;25:1759–66.

    Article  PubMed  CAS  Google Scholar 

  21. Gomez-Ambrosi J, Azcona C, Patino-Garcia A, Fruhbeck G. Serum amyloid A concentration is increased in obese children and adolescents. J Pediatr. 2008;153:71–5.

    Article  PubMed  CAS  Google Scholar 

  22. Leinonen E, Hurt-Camejo E, Wiklund O, Hulten LM, Hiukka A, Taskinen M-R. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis. 2003;166:387–94.

    Article  PubMed  CAS  Google Scholar 

  23. Catalan V, Gomez-Ambrosi J, Ramirez B, Rotellar F, Pastor C, Silva C, et al. Proinflammatory cytokines in obesity: impact of type 2 diabetes mellitus and gastric bypass. Obes Surg. 2007;17:1464–74.

    Article  PubMed  Google Scholar 

  24. Poitou C, Coupaye M, Laaban J-P, Coussieu C, Bedel JF, Bouillot J-L, et al. Serum amyloid A and obstructive sleep apnea syndrome before and after surgically-induced weight loss in morbidly obese subjects. Obes Surg. 2006;16:1475–81.

    Article  PubMed  Google Scholar 

  25. Poitou C, Coussieu C, Rouault C, Coupaye M, Cancello R, Bedel J-F, et al. Serum amyloid A: a marker of adiposity-induced low-grade inflammation but not of metabolic status. Obesity (Silver Spring). 2006;14:309–18.

    Article  CAS  Google Scholar 

  26. Gomez-Ambrosi J, Salvador J, Rotellar F, Silva C, Catalan V, Rodriguez A, et al. Increased serum amyloid A concentrations in morbid obesity decrease after gastric bypass. Obes Surg. 2006;16:262–9.

    Article  PubMed  Google Scholar 

  27. Holdstock C, Lind L, Engstrom BE, Ohrvall M, Sundbom M, Larsson A, et al. CRP reduction following gastric bypass surgery is most pronounced in insulin-sensitive subjects. Int J Obes (Lond). 2005;29:1275–80.

    Article  CAS  Google Scholar 

  28. Campbell PT, Campbell KL, Wener MH, Wood BL, Potter JD, McTiernan A, et al. A yearlong exercise intervention decreases CRP among obese postmenopausal women. Med Sci Sports Exerc. 2009;41:1533–9.

    Article  PubMed  Google Scholar 

  29. Lappalainen T, Kolehmainen M, Schwab U, Pulkkinen L, Laaksonen DE, Rauramaa R, et al. Serum concentrations and expressions of serum amyloid A and leptin in adipose tissue are interrelated: the Genobin Study. Eur J Endocrinol. 2008;158:333–41.

    Article  PubMed  CAS  Google Scholar 

  30. Salas-Salvado J, Bullo M, Garcia-Lorda P, Figueredo R, Del Castillo D, Bonada A, et al. Subcutaneous adipose tissue cytokine production is not responsible for the restoration of systemic inflammation markers during weight loss. Int J Obes (Lond). 2006;30:1714–20.

    Article  CAS  Google Scholar 

  31. O’Brien KD, Brehm BJ, Seeley RJ, Bean J, Wener MH, Daniels S, et al. Diet-induced weight loss is associated with decreases in plasma serum amyloid A and C-reactive protein independent of dietary macronutrient composition in obese subjects. J Clin Endocrinol Metab. 2005;90:2244–9.

    Article  PubMed  CAS  Google Scholar 

  32. Danesh J, Muir J, Wong YK, Ward M, Gallimore JR, Pepys MB. Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J. 1999;20:954–9.

    Article  PubMed  CAS  Google Scholar 

  33. Carter KW, Hung J, Powell BL, Wiltshire S, Foo BTX, Leow YC, et al. Association of interleukin-1 gene polymorphisms with central obesity and metabolic syndrome in a coronary heart disease population. Hum Genet. 2008;124:199–206.

    Article  PubMed  CAS  Google Scholar 

  34. Roytblat L, Rachinsky M, Fisher A, Greemberg L, Shapira Y, Doudevani A, et al. Raised interleukin-6 levels in obese patients. Obes Res. 2000;8:673–5.

    Article  PubMed  CAS  Google Scholar 

  35. Jiao P, Chen Q, Shah S, Du J, Tao B, Tzameli I, et al. Obesity-related upregulation of monocyte chemotactic factors in adipocytes involvement of nuclear factor-kappa B and c-Jun NH2-terminal kinase pathways. Diabetes. 2009;58:104–15.

    Article  PubMed  CAS  Google Scholar 

  36. Chacon MR, Fernandez-Real JM, Richart C, Megia A, Gomez JM, Miranda M, et al. Monocyte chemoattractant protein-1 in obesity and type 2 diabetes. Insulin sensitivity study. Obesity. 2007;15:664–72.

    Article  PubMed  CAS  Google Scholar 

  37. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa KI, Kitazawa R, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. 2006;116:1494–505.

    Article  PubMed  CAS  Google Scholar 

  38. Sola E, Vaya A, Espana F, Castello R, Ramon LA, Hernandez-Mijares A, et al. Plasminogen activator inhibitor-1 levels in severe and morbid obesity. Effect of weight loss and influence of 4G/5G polymorphism. Thromb Res. 2008;122:320–7.

    Article  PubMed  CAS  Google Scholar 

  39. Pou KM, Massaro JM, Hoffmann U, Vasan RS, Maurovich-Horvat P, Larson MG, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress—the Framingham Heart Study. Circulation. 2007;116:1234–41.

    Article  PubMed  CAS  Google Scholar 

  40. Greenfield JR, Samaras K, Jenkins AB, Kelly PJ, Spector TD, Gallimore JR, et al. Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation. 2004;109:3022–8.

    Article  PubMed  CAS  Google Scholar 

  41. Madsen EL, Rissanen A, Bruun JM, Skogstrand K, Tonstad S, Hougaard DM, et al. Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol. 2008;158:179–87.

    Article  PubMed  CAS  Google Scholar 

  42. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women—a randomized trial. JAMA. 2003;289:1799–804.

    Article  PubMed  CAS  Google Scholar 

  43. Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery induced weight loss. Diabetes. 2005;54:2277–86.

    Article  PubMed  CAS  Google Scholar 

  44. Lee CG, Carr MC, Murdoch SJ, Mitchell E, Woods NF, Wener MH, et al. Adipokines, inflammation, and visceral adiposity across the menopausal transition: a prospective study. J Clin Endocrinol Metab. 2009;94:1104–10.

    Article  PubMed  CAS  Google Scholar 

  45. Libby P, Ridker PM. Novel inflammatory markers of coronary risk—theory versus practice. Circulation. 1999;100:1148–50.

    PubMed  CAS  Google Scholar 

  46. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation. 2004;109:IV6–19.

    PubMed  Google Scholar 

  47. Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome—insights from therapeutic interventions. J Am Coll Cardiol. 2005;46:1978–85.

    Article  PubMed  CAS  Google Scholar 

  48. Yang R-Z, Lee M-J, Hu H, Pollin TI, Ryan AS, Nicklas BJ, et al. Acute-phase serum amyloid A: an inflammatory adipokine, potential link between obesity, its metabolic complications. PLoS Med. 2006;3:e287.

    Article  PubMed  CAS  Google Scholar 

  49. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid-A protein in severe unstable angina. N Engl J Med. 1994;331:417–24.

    Article  PubMed  CAS  Google Scholar 

  50. Meek RL, Urielishoval S, Benditt EP. Expression of apolipoprotein serum amyloid-A messenger-RNA in human atherosclerotic lesions and cultured vascular cells—implications for serum amyloid-A function. Proc Natl Acad Sci USA. 1994;91:3186–90.

    Article  PubMed  CAS  Google Scholar 

  51. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Szarek M, Waters DD, et al. Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arterioscler Thromb Vasc Biol. 2008;28:142–7.

    Article  PubMed  CAS  Google Scholar 

  52. Helmersson J, Vessby B, Larsson A, Basu S. Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation. 2004;109:1729–34.

    Article  PubMed  CAS  Google Scholar 

  53. Scheja L, Heese B, Zitzer H, Michael MD, Siesky AM, Pospisil H, et al. Acute-phase serum amyloid A as a marker of insulin resistance in mice. Exp Diabetes Res. 2008;2008:230837.

    PubMed  Google Scholar 

  54. Jacobs M, van Greevenbroek MMJ, van der Kallen CJH, Ferreira I, Blaak EE, Feskens EJM, et al. Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. Eur J Clin Invest. 2009;39:437–44.

    Article  PubMed  CAS  Google Scholar 

  55. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–43.

    Article  PubMed  CAS  Google Scholar 

  56. Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation. 2004;109:726–32.

    Article  PubMed  CAS  Google Scholar 

  57. Lee KWJ, Hill JS, Walley KR, Frohlich JJ. Relative value of multiple plasma biomarkers as risk factors for coronary artery disease and death in an angiography cohort. CMAJ. 2006;174:461–6.

    PubMed  Google Scholar 

  58. Brea D, Sobrino T, Blanco M, Fraga M, Agulla J, Rodriguez-Yanez M, et al. Usefulness of haptoglobin and serum amyloid A proteins as biomarkers for atherothrombotic ischemic stroke diagnosis confirmation. Atherosclerosis. 2009;205:561–7.

    Article  PubMed  CAS  Google Scholar 

  59. Rallidis LS, Vikelis M, Panagiotakos DB, Rizos I, Zolindaki MG, Kaliva K, et al. Inflammatory markers and in-hospital mortality in acute ischaemic stroke. Atherosclerosis. 2006;189:193–7.

    Article  PubMed  CAS  Google Scholar 

  60. Wohlin M, Helmersson J, Sundstrom J, Arnlov J, Vessby B, Larsson A, et al. Both cyclooxygenase- and cytokine-mediated inflammation are associated with carotid intima-media thickness. Cytokine. 2007;38:130–6.

    Article  PubMed  CAS  Google Scholar 

  61. Uurtuya S, Kotani K, Koibuchi H, Taniguchi N, Yamada T. Serum amyloid A protein and carotid intima-media thickness in healthy young subjects. J Atheroscler Thromb. 2009;16:299–300.

    PubMed  CAS  Google Scholar 

  62. Maier W, Altwegg LA, Corti R, Gay S, Hersberger M, Maly FE, et al. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation. 2005;111:1355–61.

    Article  PubMed  CAS  Google Scholar 

  63. Ley SH, Harris SB, Connelly PW, Mamakeesick M, Gittelsohn J, Hegele RA, et al. Adipokines and incident type 2 diabetes in an aboriginal Canadian corrected population: the Sandy Lake Health and Diabetes Project. Diabetes Care. 2008;31:1410–5.

    Article  PubMed  CAS  Google Scholar 

  64. Pitsavos C, Tampourlou M, Panagiotakos DB, Skoumas Y, Chrysohoou C, Nomikos T, et al. Association between low-grade systemic inflammation and type 2 diabetes mellitus among men and women from the ATTICA study. Rev Diabet Stud. 2007;4:98–104.

    Article  PubMed  Google Scholar 

  65. Herder C, Peltonen M, Koenig W, Kraft I, Muller-Scholze S, Martin S, et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes. 2006;55:2340–6.

    Article  PubMed  CAS  Google Scholar 

  66. Ebeling P, Teppo AM, Koistinen HA, Viikari J, Ronnemaa T, Nissen M, et al. Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes. Diabetologia. 1999;42:1433–8.

    Article  PubMed  CAS  Google Scholar 

  67. Ghanim H, Dhindsa S, Aljada A, Chaudhuri A, Viswanathan P, Dandona P. Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. J Clin Endocrinol Metab. 2006;91:3553–8.

    Article  PubMed  CAS  Google Scholar 

  68. Lago F, Dieguez C, Gomez-Reino J, Gualillo O. Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol. 2007;3:716–24.

    Article  PubMed  CAS  Google Scholar 

  69. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6:772–83.

    Article  PubMed  CAS  Google Scholar 

  70. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005;96:939–49.

    Article  PubMed  CAS  Google Scholar 

  71. Lin Y, Rajala MW, Berger JP, Moller DE, Barzilai N, Scherer PE. Hyperglycemia-induced production of acute phase reactants in adipose tissue. J Biol Chem. 2001;276:42077–83.

    Article  PubMed  CAS  Google Scholar 

  72. Subramanian S, Han CY, Chiba T, McMillen TS, Wang SA, Haw A III et al. Dietary cholesterol worsens adipose tissue macrophage accumulation and atherosclerosis in obese LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2008;28:685–91.

    Article  PubMed  CAS  Google Scholar 

  73. Chiba T, Han CY, Vaisar T, Shimokado K, Kargi A, Chen M-H, et al. Serum amyloid A3 does not contribute to circulating SAA levels. J Lipid Res. 2009;50:1353–62.

    Article  PubMed  CAS  Google Scholar 

  74. Lewis KE, Kirk EA, McDonald TO, Wang S, Wight TN, O’Brien KD, et al. Increase in serum amyloid A evoked by dietary cholesterol is associated with increased atherosclerosis in mice. Circulation. 2004;110:540–5.

    Article  PubMed  CAS  Google Scholar 

  75. Kim F, Pham M, Maloney E, Rizzo NO, Morton GJ, Wisse BE, et al. Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset of peripheral insulin resistance. Arterioscler Thromb Vasc Biol. 2008;28:1982–8.

    Article  PubMed  CAS  Google Scholar 

  76. Ye XY, Xue YM, Sha JP, Li CZ, Zhen ZJ. Serum amyloid A attenuates cellular insulin sensitivity by increasing JNK activity in 3T3–L1 adipocytes. J Endocrinol Invest. 2009;32:568–75.

    PubMed  CAS  Google Scholar 

  77. Arner P. Control of lipolysis and its relevance to development of obesity in man. Diabetes Metab Rev. 1988;4:507–15.

    Article  PubMed  CAS  Google Scholar 

  78. Chen CH, Wang PH, Liu BH, Hsu HH, Mersmann HJ, Ding ST. Serum amyloid A protein regulates the expression of porcine genes related to lipid metabolism. J Nutr. 2008;138:674–9.

    PubMed  CAS  Google Scholar 

  79. Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2003;23:283–8.

    Article  PubMed  CAS  Google Scholar 

  80. Hetzel J, Balletshofer B, Rittig K, Walcher D, Kratzer W, Hombach V, et al. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol. 2005;25:1804–9.

    Article  PubMed  CAS  Google Scholar 

  81. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab. 2004;89:2728–35.

    Article  PubMed  CAS  Google Scholar 

  82. Chaudhuri A, Janicke D, Wilson MF, Tripathy D, Garg R, Bandyopadhyay A et al. Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation. 2004;109:849–54.

    Article  PubMed  CAS  Google Scholar 

  83. Zadelaar ASM, Boesten LSM, Jukema JW, van Vlijmen BJM, Kooistra T, Emeis JJ, et al. Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice. Arterioscler Thromb Vasc Biol. 2006;26:2560–6.

    Article  PubMed  CAS  Google Scholar 

  84. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108:1560–6.

    Article  PubMed  CAS  Google Scholar 

  85. Schillinger M, Exner M, Mlekusch W, Amighi J, Sabeti S, Muellner M, et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J. 2004;25:742–8.

    Article  PubMed  CAS  Google Scholar 

  86. Kleemann R, Princen HMG, Emeis JJ, Jukema JW, Fontijn RD, Horrevoets AJG, et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation. 2003;108:1368–74.

    Article  PubMed  CAS  Google Scholar 

  87. Verschuren L, Kleemann R, Offerman EH, Szalai AJ, Emeis SJ, Princen HMG, et al. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice. Arterioscler Thromb Vasc Biol. 2005;25:161–7.

    PubMed  CAS  Google Scholar 

  88. Derosa G, Tinelli C, Maffioli P. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. Diabetes Obes Metab. 2009;11:1091–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The analysis was supported by National Natural Science Foundation of China (NSFC 30800401). We thank the following persons for their help in the preparation of the manuscript: Prof. Jiaying Liu from East China Normal University, Dr. Ying Xu from the University of Pennsylvania, and Dr. Yuntong Nie from National University of Singapore.

Author information

Authors and Affiliations

  1. Advanced Institute of NBIC Integrated Drug Discovery and Development, East China Normal University, North Zhongshan Road #3663, Shanghai, 200062, People’s Republic of China

    Yulan Zhao, Xuegui Shi, Jie Liu & Shuli Zhou

  2. Central Laboratory, Wuhan Children’s Hospital, Wuhan, People’s Republic of China

    Xuelian He

  3. Department of General Internal Medicine, Peking Union Medical School Hospital, Beijing, People’s Republic of China

    Chengjin Huang

  4. Department of Paediatrics, National University of Singapore, Singapore, Singapore

    Chew-Kiat Heng

Authors
  1. Yulan Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xuelian He
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xuegui Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chengjin Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jie Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shuli Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chew-Kiat Heng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yulan Zhao.

Additional information

Responsible Editor: M. Parnham.

Y. Zhao and X. He contributed equally.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhao, Y., He, X., Shi, X. et al. Association between serum amyloid A and obesity: a meta-analysis and systematic review. Inflamm. Res. 59, 323–334 (2010). https://doi.org/10.1007/s00011-010-0163-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00011-010-0163-y

Keywords

Search

Navigation